Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 3
2009 6
2010 3
2011 4
2012 2
2013 6
2014 8
2015 11
2016 16
2017 13
2018 20
2019 26
2020 22
2021 25
2022 16
2023 15
2024 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
Clinical implications of PTEN loss in prostate cancer.
Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL. Jamaspishvili T, et al. Among authors: lotan tl. Nat Rev Urol. 2018 Apr;15(4):222-234. doi: 10.1038/nrurol.2018.9. Epub 2018 Feb 20. Nat Rev Urol. 2018. PMID: 29460925 Free PMC article. Review.
A PRC2-independent function for EZH2 in regulating rRNA 2'-O methylation and IRES-dependent translation.
Yi Y, Li Y, Meng Q, Li Q, Li F, Lu B, Shen J, Fazli L, Zhao D, Li C, Jiang W, Wang R, Liu Q, Szczepanski A, Li Q, Qin W, Weiner AB, Lotan TL, Ji Z, Kalantry S, Wang L, Schaeffer EM, Niu H, Dong X, Zhao W, Chen K, Cao Q. Yi Y, et al. Among authors: lotan tl. Nat Cell Biol. 2021 Apr;23(4):341-354. doi: 10.1038/s41556-021-00653-6. Epub 2021 Apr 1. Nat Cell Biol. 2021. PMID: 33795875 Free PMC article.
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, Bentzen SM, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, Tran PT. Deek MP, et al. Among authors: lotan tl. J Clin Oncol. 2022 Oct 10;40(29):3377-3382. doi: 10.1200/JCO.22.00644. Epub 2022 Aug 24. J Clin Oncol. 2022. PMID: 36001857 Free PMC article.
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.
Shenderov E, De Marzo AM, Lotan TL, Wang H, Chan S, Lim SJ, Ji H, Allaf ME, Chapman C, Moore PA, Chen F, Sorg K, White AM, Church SE, Hudson B, Fields PA, Hu S, Denmeade SR, Pienta KJ, Pavlovich CP, Ross AE, Drake CG, Pardoll DM, Antonarakis ES. Shenderov E, et al. Among authors: lotan tl. Nat Med. 2023 Apr;29(4):888-897. doi: 10.1038/s41591-023-02284-w. Epub 2023 Apr 3. Nat Med. 2023. PMID: 37012549 Free PMC article. Clinical Trial.
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Antonarakis ES, et al. Among authors: lotan tl. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3. N Engl J Med. 2014. PMID: 25184630 Free PMC article.
Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer.
Mori JO, Elhussin I, Brennen WN, Graham MK, Lotan TL, Yates CC, De Marzo AM, Denmeade SR, Yegnasubramanian S, Nelson WG, Denis GV, Platz EA, Meeker AK, Heaphy CM. Mori JO, et al. Among authors: lotan tl. Nat Rev Urol. 2024 May;21(5):258-273. doi: 10.1038/s41585-023-00827-x. Epub 2023 Oct 31. Nat Rev Urol. 2024. PMID: 37907729 Review.
RAD21 promotes oncogenesis and lethal progression of prostate cancer.
Su XA, Stopsack KH, Schmidt DR, Ma D, Li Z, Scheet PA, Penney KL, Lotan TL, Abida W, DeArment EG, Lu K, Janas T, Hu S, Vander Heiden MG, Loda M, Boselli M, Amon A, Mucci LA. Su XA, et al. Among authors: lotan tl. Proc Natl Acad Sci U S A. 2024 Sep 3;121(36):e2405543121. doi: 10.1073/pnas.2405543121. Epub 2024 Aug 27. Proc Natl Acad Sci U S A. 2024. PMID: 39190349 Free PMC article.
MLH1 Loss in Primary Prostate Cancer.
Nourmohammadi Abadchi S, Sena LA, Antonarakis ES, Pritchard CC, Eshleman JR, Konnick EQ, Salipante SJ, Shenderov E, Lotan TL. Nourmohammadi Abadchi S, et al. Among authors: lotan tl. JCO Precis Oncol. 2023 May;7:e2200611. doi: 10.1200/PO.22.00611. JCO Precis Oncol. 2023. PMID: 37196219 Free PMC article.
A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
Weiner AB, Liu Y, Hakansson A, Zhao X, Proudfoot JA, Ho J, Zhang JH, Li EV, Karnes RJ, Den RB, Kishan AU, Reiter RE, Hamid AA, Ross AE, Tran PT, Davicioni E, Spratt DE, Attard G, Lotan TL, Lee Kiang Chua M, Sweeney CJ, Schaeffer EM. Weiner AB, et al. Among authors: lotan tl. Cancer. 2023 Jul 15;129(14):2169-2178. doi: 10.1002/cncr.34790. Epub 2023 Apr 14. Cancer. 2023. PMID: 37060201 Free article.
181 results